{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T07:32:39Z","timestamp":1793172759799,"version":"4.5.0"},"reference-count":125,"publisher":"Elsevier BV","issue":"20","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.bmcl.2019.126658","type":"journal-article","created":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T13:21:02Z","timestamp":1567516862000},"page":"126658","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Inhaled Janus Kinase (JAK) inhibitors for the treatment of asthma"],"prefix":"10.1016","volume":"29","author":[{"given":"Mark","family":"Zak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hart S.","family":"Dengler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi S.","family":"Rajapaksa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2019.126658_b0005","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/nri1226","article-title":"Regulation of JAK-STAT signalling in the immune system","volume":"3","author":"Shuai","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.bmcl.2019.126658_b0010","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.4049\/jimmunol.178.5.2623","article-title":"The JAK-STAT signaling pathway: input and output integration","volume":"178","author":"Murray","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.bmcl.2019.126658_b0015","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention","volume":"66","author":"O'Shea","year":"2015","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.bmcl.2019.126658_b0020","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1021\/jm401490p","article-title":"Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases","volume":"57","author":"Clark","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2019.126658_b0025","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1182\/blood-2009-08-235846","article-title":"Alternative modes of GM-CSF receptor activation revealed using activated mutants of the common beta-subunit","volume":"115","author":"Perugini","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bmcl.2019.126658_b0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1081-1206(10)60826-5","article-title":"Asthma: a syndrome composed of heterogeneous diseases","volume":"101","author":"Borish","year":"2008","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.bmcl.2019.126658_b0035","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/cea.12880","article-title":"Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications","volume":"47","author":"Robinson","year":"2017","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.bmcl.2019.126658_b0040","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jaci.2010.11.037","article-title":"Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome","volume":"127","author":"Lotvall","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.bmcl.2019.126658_b0045","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.jaci.2016.06.061","article-title":"Asthma phenotypes in inner-city children","volume":"138","author":"Zoratti","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.bmcl.2019.126658_b0050","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1001\/jama.2018.3808","article-title":"Medications for Asthma","volume":"319","author":"Sobieraj","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.bmcl.2019.126658_b0055","unstructured":"https:\/\/www.cdc.gov\/asthma\/asthma_stats\/uncontrolled_asthma.htm. Accessed 4\/23\/2019."},{"key":"10.1016\/j.bmcl.2019.126658_b0060","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.jaip.2019.03.022","article-title":"New targeted therapies for uncontrolled asthma","volume":"7","author":"Corren","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.bmcl.2019.126658_b0065","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4103\/1817-1737.32228","article-title":"Classification of asthma according to revised 2006 GINA: evolution from severity to control","volume":"2","author":"Koshak","year":"2007","journal-title":"Ann Thorac Med"},{"key":"10.1016\/j.bmcl.2019.126658_b0070","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1183\/13993003.00853-2015","article-title":"A summary of the new GINA strategy: a roadmap to asthma control","volume":"46","author":"Reddel","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.bmcl.2019.126658_b0075","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s11882-014-0437-5","article-title":"Relevance of allergy in adult asthma","volume":"14","author":"Mathur","year":"2014","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.bmcl.2019.126658_b0080","doi-asserted-by":"crossref","first-page":"00024","DOI":"10.1183\/23120541.00024-2015","article-title":"Management of the patient with eosinophilic asthma: a new era begins","volume":"1","author":"de Groot","year":"2015","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.bmcl.2019.126658_b0085","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200903-0392OC","article-title":"T-helper type 2-driven inflammation defines major subphenotypes of asthma","volume":"180","author":"Woodruff","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.bmcl.2019.126658_b0090","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.iac.2016.03.004","article-title":"Biomarkers in Severe Asthma","volume":"36","author":"Wan","year":"2016","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.bmcl.2019.126658_b0095","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1002\/eji.201041195","article-title":"TSLP enhances the function of helper type 2 cells","volume":"41","author":"Kitajima","year":"2011","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.bmcl.2019.126658_b0100","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.anai.2018.01.009","article-title":"Cytokine-targeting biologics for allergic diseases","volume":"120","author":"Lawrence","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.bmcl.2019.126658_b0105","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 inflammation in disease","volume":"15","author":"Gandhi","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmcl.2019.126658_b0110","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/1465-9921-14-93","article-title":"A randomized, controlled trial to evaluate the effect of an anti-interleukin-9 monoclonal antibody in adults with uncontrolled asthma","volume":"14","author":"Oh","year":"2013","journal-title":"Respir Res"},{"key":"10.1016\/j.bmcl.2019.126658_b0115","doi-asserted-by":"crossref","first-page":"180","DOI":"10.2174\/187152811795564073","article-title":"Biology of the interleukin-9 pathway and its therapeutic potential for the treatment of asthma","volume":"10","author":"Oh","year":"2011","journal-title":"Inflamm Allergy Drug Targets"},{"key":"10.1016\/j.bmcl.2019.126658_b0120","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in Adults with Uncontrolled Asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmcl.2019.126658_b0125","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2213-2600(18)30184-X","article-title":"Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials","volume":"6","author":"Panettieri","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.bmcl.2019.126658_b0130","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S2213-2600(18)30201-7","article-title":"Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial","volume":"6","author":"Russell","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.bmcl.2019.126658_b0135","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S2213-2600(16)30265-X","article-title":"Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials","volume":"4","author":"Hanania","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.bmcl.2019.126658_b0140","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmcl.2019.126658_b0145","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmcl.2019.126658_b0150","doi-asserted-by":"crossref","DOI":"10.1088\/1752-7163\/aa7f0e","article-title":"Perspectives on exhaled nitric oxide","volume":"11","author":"Ricciardolo","year":"2017","journal-title":"J Breath Res"},{"key":"10.1016\/j.bmcl.2019.126658_b0155","unstructured":"Phase I trial to evaluate the safety and tolerability of GDC-0214 in healthy volunteers and patients with mild asthma. ACTRN12617001227381. https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=373446. Accessed 8\/26\/2019."},{"key":"10.1016\/j.bmcl.2019.126658_b0160","unstructured":"A Study in Healthy Volunteers and Patients with Mild Asthma to Investigate the Safety, Anti-inflammatory Effect of Inhaled AZD0449. NCT03766399. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03766399. Accessed 4\/23\/2019."},{"key":"10.1016\/j.bmcl.2019.126658_h0165","unstructured":"Theravance Biopharma Inc (TBPH) Q4 2018 Earnings Conference Call Transcript. https:\/\/www.fool.com\/earnings\/call-transcripts\/2019\/02\/26\/theravance-biopharma-inc-tbph-q4-2018-earnings-con.aspx. Accessed 4\/26\/2019."},{"key":"10.1016\/j.bmcl.2019.126658_h9000","unstructured":"Theravance press release. https:\/\/investor.theravance.com\/node\/11351\/pdf. Accessed 9\/9\/2019."},{"key":"10.1016\/j.bmcl.2019.126658_b0170","unstructured":"Single and Multiple Ascending Dose Study of TD-8236 by Inhalation. NCT03652038. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03652038?term=td8236&rank=1. Accessed 4\/23\/2019."},{"key":"10.1016\/j.bmcl.2019.126658_b0175","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/ni.3049","article-title":"The immunology of asthma","volume":"16","author":"Lambrecht","year":"2015","journal-title":"Nat Immunol"},{"key":"10.1016\/j.bmcl.2019.126658_b0180","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2174\/187152806779010909","article-title":"Interferon-gamma as a possible target in chronic asthma","volume":"5","author":"Kumar","year":"2006","journal-title":"Inflamm Allergy Drug Targets"},{"key":"10.1016\/j.bmcl.2019.126658_b0185","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.it.2017.07.003","article-title":"Neutrophilic Inflammation in asthma and association with disease severity","volume":"38","author":"Ray","year":"2017","journal-title":"Trends Immunol"},{"key":"10.1016\/j.bmcl.2019.126658_b0190","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/S2213-2600(16)30048-0","article-title":"Plasma interleukin-6 concentrations, metabolic dysfunction, and asthma severity: a cross-sectional analysis of two cohorts","volume":"4","author":"Peters","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.bmcl.2019.126658_b0195","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1172\/JCI80911","article-title":"High IFN-gamma and low SLPI mark severe asthma in mice and humans","volume":"125","author":"Raundhal","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bmcl.2019.126658_b0205","doi-asserted-by":"crossref","first-page":"8468","DOI":"10.1021\/jm1004286","article-title":"Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection","volume":"53","author":"Flanagan","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2019.126658_b0210","unstructured":"Rodgers JD, Shepard S, Li Y-L, et al. Azetidine and cyclobutane derivatives as jak inhibitors. WO2009114512A1."},{"key":"10.1016\/j.bmcl.2019.126658_b0215","article-title":"Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis","author":"Taylor","year":"2019581","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.bmcl.2019.126658_b0220","doi-asserted-by":"crossref","first-page":"59","DOI":"10.33590\/emjrheumatol\/10312907","article-title":"JAK INHIBITORS in the treatment algorithm of rheumatoid arthritis: a review","volume":"5","author":"Bellinvia","year":"2018","journal-title":"EMJ Rheumatol"},{"issue":"Supplement_1","key":"10.1016\/j.bmcl.2019.126658_b0225","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/key287","article-title":"Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis","volume":"58","author":"Harigai","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"Supplement_1","key":"10.1016\/j.bmcl.2019.126658_b0230","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/key256","article-title":"Clinical efficacy of new JAK inhibitors under development. Just more of the same?","volume":"58","author":"Westhovens","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.bmcl.2019.126658_b0235","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1016\/j.bmc.2018.08.005","article-title":"Discovery and structural characterization of peficitinib (ASP015K) as a novel and potent JAK inhibitor","volume":"26","author":"Hamaguchi","year":"2018","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmcl.2019.126658_b0240","unstructured":"Astellas press release. https:\/\/www.astellas.com\/en\/news\/14651. Accessed 4\/23\/2019."},{"key":"10.1016\/j.bmcl.2019.126658_b0245","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s41927-018-0031-x","article-title":"In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)","volume":"2","author":"Parmentier","year":"2018","journal-title":"BMC Rheumatol"},{"key":"10.1016\/j.bmcl.2019.126658_b0250","unstructured":"AbbVie press release. https:\/\/news.abbvie.com\/news\/press-releases\/abbvie-receives-fda-approval-rinvoq-upadacitinib-an-oral-jak-inhibitor-for-treatment-moderate-to-severe-rheumatoid-arthritis.htm. Accessed 8\/26\/2019."},{"key":"10.1016\/j.bmcl.2019.126658_b0255","doi-asserted-by":"crossref","first-page":"9323","DOI":"10.1021\/jm501262q","article-title":"Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634","volume":"57","author":"Menet","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2019.126658_b0260","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1021\/acs.jmedchem.7b01598","article-title":"Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): a selective JAK1 clinical candidate for the treatment of autoimmune diseases","volume":"61","author":"Vazquez","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2019.126658_b0265","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1021\/acs.jmedchem.6b01694","article-title":"Design of a Janus Kinase 3 (JAK3) specific inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop -2-en-1-one (PF-06651600) allowing for the interrogation of JAK3 signaling in humans","volume":"60","author":"Thorarensen","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2019.126658_b0270","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.9b00444","article-title":"Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165","author":"Wrobleski","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2019.126658_b0275","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nrd.2017.267","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"17","author":"Schwartz","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmcl.2019.126658_b0280","unstructured":"https:\/\/www.cdc.gov\/asthma\/most_recent_national_asthma_data.htm. Accessed 4\/23\/2019."},{"key":"10.1016\/j.bmcl.2019.126658_b0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.rmed.2015.11.002","article-title":"Achieving asthma control with ICS\/LABA: a review of strategies for asthma management and prevention","volume":"111","author":"Aalbers","year":"2016","journal-title":"Respir Med"},{"key":"10.1016\/j.bmcl.2019.126658_b0290","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nrd2153","article-title":"Inhaling medicines: delivering drugs to the body through the lungs","volume":"6","author":"Patton","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmcl.2019.126658_b0295","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2174\/138920012800166571","article-title":"Optimisation of DMPK by the inhaled route: challenges and approaches","volume":"13","author":"Cooper","year":"2012","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.bmcl.2019.126658_b0300","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1164\/ajrccm.164.6.2010107","article-title":"Long-acting inhaled beta(2)-agonist therapy in asthma","volume":"164","author":"Kips","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.bmcl.2019.126658_b0305","doi-asserted-by":"crossref","first-page":"7797","DOI":"10.1021\/jm200677b","article-title":"Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease","volume":"54","author":"Millan","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2019.126658_b0310","doi-asserted-by":"crossref","first-page":"8591","DOI":"10.1021\/acs.jmedchem.7b01215","article-title":"Selective nonsteroidal glucocorticoid receptor modulators for the inhaled treatment of pulmonary diseases","volume":"60","author":"Hemmerling","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2019.126658_b0315","doi-asserted-by":"crossref","first-page":"9551","DOI":"10.1021\/acs.jmedchem.8b00873","article-title":"Discovery of a novel inhaled PI3Kdelta inhibitor for the treatment of respiratory diseases","volume":"61","author":"Erra","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2019.126658_b0320","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1124\/jpet.108.147538","article-title":"Novel tight-binding inhibitory factor-kappaB kinase (IKK-2) inhibitors demonstrate target-specific anti-inflammatory activities in cellular assays and following oral and local delivery in an in vivo model of airway inflammation","volume":"330","author":"Sommers","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bmcl.2019.126658_b0325","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.bmc.2010.12.027","article-title":"Aminopyridinecarboxamide-based inhaled IKK-2 inhibitors for asthma and COPD: structure-activity relationship","volume":"19","author":"Xie","year":"2011","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmcl.2019.126658_b0330","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1124\/jpet.110.173690","article-title":"GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization","volume":"337","author":"Tralau-Stewart","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bmcl.2019.126658_b0335","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/0024-3205(93)90312-Q","article-title":"Ba 679 BR, a novel long-acting anticholinergic bronchodilator","volume":"52","author":"Disse","year":"1993","journal-title":"Life Sci"},{"key":"10.1016\/j.bmcl.2019.126658_b0340","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/0024-3205(95)00020-7","article-title":"Tiotropium bromide (Ba 679 BR), a novel long-acting muscarinic antagonist for the treatment of obstructive airways disease","volume":"56","author":"Barnes","year":"1995","journal-title":"Life Sci"},{"key":"10.1016\/j.bmcl.2019.126658_b0345","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/S0149-2918(01)80113-2","article-title":"A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate","volume":"23","author":"Crim","year":"2001","journal-title":"Clin Ther"},{"key":"10.1016\/j.bmcl.2019.126658_b0350","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1183\/09031936.94.07030569","article-title":"Why are long-acting beta-adrenoceptor agonists long-acting?","volume":"7","author":"Anderson","year":"1994","journal-title":"Eur Respir J"},{"key":"10.1016\/j.bmcl.2019.126658_b0355","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrd1472","article-title":"Tiotropium bromide","volume":"3","author":"Mundy","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmcl.2019.126658_b0360","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2017.11.013","article-title":"Pulmonary absorption - estimation of effective pulmonary permeability and tissue retention of ten drugs using an ex vivo rat model and computational analysis","volume":"124","author":"Eriksson","year":"2018","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.bmcl.2019.126658_b0365","doi-asserted-by":"crossref","first-page":"7381","DOI":"10.1021\/acs.jmedchem.5b00767","article-title":"Optimization of novel indazoles as highly potent and selective inhibitors of phosphoinositide 3-kinase delta for the treatment of respiratory disease","volume":"58","author":"Down","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2019.126658_b0370","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1208\/s12248-015-9751-7","article-title":"In vitro, pharmacokinetic, pharmacodynamic, and safety comparisons of single and combined administration of tiotropium and salmeterol in COPD patients using different dry powder inhalers","volume":"17","author":"Horhota","year":"2015","journal-title":"AAPS j"},{"key":"10.1016\/j.bmcl.2019.126658_b0375","doi-asserted-by":"crossref","first-page":"7901","DOI":"10.1021\/acs.jmedchem.6b00703","article-title":"Optimization of platelet-derived growth factor receptor (PDGFR) inhibitors for duration of action, as an inhaled therapy for lung remodeling in pulmonary arterial hypertension","volume":"59","author":"Shaw","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2019.126658_b0380","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1124\/jpet.110.173641","article-title":"In vivo characterization of GSK256066, a high-affinity inhaled phosphodiesterase 4 inhibitor","volume":"337","author":"Nials","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bmcl.2019.126658_b0385","doi-asserted-by":"crossref","first-page":"6640","DOI":"10.1021\/jm1005989","article-title":"Inhalation by design: novel ultra-long-acting beta(2)-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup","volume":"53","author":"Glossop","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2019.126658_b0390","doi-asserted-by":"crossref","first-page":"89s","DOI":"10.1378\/chest.120.3_suppl.89S","article-title":"Delivery options and devices for aerosolized therapeutics","volume":"120","author":"Anderson","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.bmcl.2019.126658_b0395","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028241","article-title":"Cilia and mucociliary clearance","volume":"9","author":"Bustamante-Marin","year":"2017","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.bmcl.2019.126658_b0400","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2174\/138945008784533561","article-title":"The \u201cclassical\u201d ovalbumin challenge model of asthma in mice","volume":"9","author":"Kumar","year":"2008","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.bmcl.2019.126658_b0405","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.4049\/jimmunol.1302984","article-title":"IL-33 and thymic stromal lymphopoietin mediate immune pathology in response to chronic airborne allergen exposure","volume":"193","author":"Iijima","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.bmcl.2019.126658_b0410","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1164\/rccm.2105079","article-title":"Anti-interleukin-9 antibody treatment inhibits airway inflammation and hyperreactivity in mouse asthma model","volume":"166","author":"Cheng","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.bmcl.2019.126658_b0415","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.cyto.2004.08.007","article-title":"Anti-IL-13 monoclonal antibody inhibits airway hyperresponsiveness, inflammation and airway remodeling","volume":"28","author":"Yang","year":"2004","journal-title":"Cytokine"},{"key":"10.1016\/j.bmcl.2019.126658_b0420","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1126\/science.282.5397.2261","article-title":"Requirement for IL-13 independently of IL-4 in experimental asthma","volume":"282","author":"Grunig","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.bmcl.2019.126658_b0425","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.clim.2008.07.015","article-title":"Local blockade of TSLP receptor alleviated allergic disease by regulating airway dendritic cells","volume":"129","author":"Shi","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1016\/j.bmcl.2019.126658_b0430","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1165\/rcmb.2003-0305OC","article-title":"Role of interleukin-5 and eosinophils in allergen-induced airway remodeling in mice","volume":"31","author":"Tanaka","year":"2004","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.bmcl.2019.126658_b0435","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao2151","article-title":"Lung-restricted inhibition of Janus kinase 1 is effective in rodent models of asthma","volume":"10","author":"Dengler","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bmcl.2019.126658_b0440","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1021\/acs.jmedchem.6b01634","article-title":"Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin","volume":"60","author":"Jones","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2019.126658_b0445","unstructured":"Thalladi VR, Zhang H, Kleinschek MA, Crater GD. Methods of treatment using a jak inhibitor compound. WO2018204233A1."},{"key":"10.1016\/j.bmcl.2019.126658_b0450","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.jaci.2013.10.036","article-title":"Janus kinase 1\/3 signaling pathways are key initiators of TH2 differentiation and lung allergic responses","volume":"133","author":"Ashino","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.bmcl.2019.126658_b0455","unstructured":"Nilsson KM, \u00c5strand ABM, Berggren AIK, et al. Jak1 selective inhibitors. WO2018134213A1."},{"key":"10.1016\/j.bmcl.2019.126658_b0460","series-title":"In Vitro Profile Of The New Pan-JAK Inhibitor Compound A. A32. New Asthma Therapies: Clinical Studies","first-page":"A1317","author":"Ramis","year":"2014"},{"key":"10.1016\/j.bmcl.2019.126658_b0465","series-title":"255th ACS National Meeting","article-title":"Discovery of LAS194046, a potent pan-JAK inhibitor for the inhaled treatment of respiratory diseases","author":"Bach","year":"2018"},{"key":"10.1016\/j.bmcl.2019.126658_b0470","article-title":"Novel inhaled pan-JAK inhibitor, LAS194046, reduces allergen-induced airway inflammation, late asthmatic response and pSTATs activation in Brown Norway rats","volume":"jpet.119.256263","author":"Calbet","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"issue":"suppl 59","key":"10.1016\/j.bmcl.2019.126658_b0475","first-page":"PA2130","article-title":"In vitro evaluation of a new potent, selective pan-Janus kinase (JAK) inhibitor VR588","volume":"46","author":"Wiegman","year":"2015","journal-title":"Eur Respir J."},{"key":"10.1016\/j.bmcl.2019.126658_b0480","series-title":"Pre-Clinical Evaluation of a Potent Janus Kinase (JAK) Inhibitor Designed for Topical Delivery in Severe Asthma","first-page":"A6483","author":"Lee","year":"2016"},{"key":"10.1016\/j.bmcl.2019.126658_b0485","series-title":"255th ACS National Meeting","article-title":"Inhaled Janus kinase 1 (JAK1) inhibitors as potential treatments for asthma","author":"Zak","year":"2018"},{"key":"10.1016\/j.bmcl.2019.126658_b0490","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1046\/j.1432-1327.1999.00719.x","article-title":"Different protein turnover of interleukin-6-type cytokine signalling components","volume":"265","author":"Siewert","year":"1999","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.bmcl.2019.126658_b0495","unstructured":"A Phase 1 Study to Evaluate Tolerability, Safety, and Pharmacokinetics of Topical PF-06263276 In Healthy Subjects. NCT01981681. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01981681. Accessed 4\/23\/2019."},{"key":"10.1016\/j.bmcl.2019.126658_b0500","unstructured":"A 12 Day Study to Evaluate a Topical Drug to Treat Plaque Psoriasis. NCT02193815. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02193815. Accessed 4\/23\/2019."},{"key":"10.1016\/j.bmcl.2019.126658_b0505","unstructured":"Benjamin N, Dabros M, Thalladi VR. JAK kinase inhibitor compounds for treatment of respiratory disease. US10183942B2."},{"key":"10.1016\/j.bmcl.2019.126658_b0510","unstructured":"Dabros M, Thalladi VR, Nzerem J, Kleinschek MA, Crater GD. Crystalline forms of a JAK inhibitor compound. US10251874B2."},{"key":"10.1016\/j.bmcl.2019.126658_b0515","unstructured":"Theravance Biopharma Announces First Subject Dosed in Phase 1 Clinical Trial of TD-8236, a Novel Inhaled pan-JAK Inhibitor. https:\/\/investor.theravance.com\/news-releases\/news-release-details\/theravance-biopharma-announces-first-subject-dosed-phase-1-1. Accessed 4\/23\/2019."},{"key":"10.1016\/j.bmcl.2019.126658_b0520","unstructured":"Calculations performed using Genentech property calculators."},{"key":"10.1016\/j.bmcl.2019.126658_b0525","unstructured":"In addition to the cited patents highlighting compound 15, an additional Theravance patent from a related series has recently published. Fatheree PR, Brandt GEL, Smith C, et al. Fused imidazo-piperidine JAK inhibitors. US10208040B2."},{"key":"10.1016\/j.bmcl.2019.126658_b0530","unstructured":"Li H, Heckrodt TJ, Chen Y, et al. Compositions and methods for inhibition of the jak pathway. WO2010085684A1."},{"key":"10.1016\/j.bmcl.2019.126658_b0535","unstructured":"AstraZeneca and Rigel Sign Worldwide License Agreement for a Potential New Treatment for Chronic Asthma. Rigel Press Release, June 19, 2012. https:\/\/www.prnewswire.com\/news-releases\/astrazeneca-and-rigel-sign-worldwide-license-agreement-for-a-potential-new-treatment-for-chronic-asthma-159547565.html. Accessed 4\/23\/2019."},{"key":"10.1016\/j.bmcl.2019.126658_b0540","unstructured":"Rigel has indicated that R256 is the same molecule as AZD0449. https:\/\/www.rigel.com\/index.php\/about-rigel\/current-partners\/astrazeneca\/. Accessed 4\/26\/2019."},{"key":"10.1016\/j.bmcl.2019.126658_b0545","unstructured":"AstraZeneca development pipeline. https:\/\/www.astrazeneca.com\/our-science\/pipeline.html. Accessed 4\/26\/2019."},{"key":"10.1016\/j.bmcl.2019.126658_b0550","series-title":"R256 is a Potent and Selective IL-13\/4 Receptor Signaling Inhibitor That Reduces Inflammation in a Mouse Model of Chronic Asthma","first-page":"A2843","author":"Taylor","year":"2012"},{"key":"10.1016\/j.bmcl.2019.126658_b0555","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1021\/acs.cgd.8b01492","article-title":"Derisking development by a cocrystallization screen of a novel selective inhaled JAK-STAT inhibitor","volume":"19","author":"Llinas","year":"2019","journal-title":"Cryst Growth Des"},{"key":"10.1016\/j.bmcl.2019.126658_b0560","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1021\/acs.jmedchem.8b00076","article-title":"Discovery and optimization of a novel series of highly selective JAK1 kinase inhibitors","volume":"61","author":"Grimster","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2019.126658_b0565","series-title":"New Inhaled Pan-JAK Inhibitor A Is Efficacious At Reducing Allergen-Induced Airway Inflammation In Rat","first-page":"A4217","author":"Ramis","year":"2014"},{"key":"10.1016\/j.bmcl.2019.126658_b0570","unstructured":"Munro A. Novel polymorphs. WO2016124464A1."},{"key":"10.1016\/j.bmcl.2019.126658_b0575","unstructured":"Holland J. Crystalline form of a JAK3 kinase inhibitor. WO2016142201A1."},{"key":"10.1016\/j.bmcl.2019.126658_b0580","unstructured":"Rosales CA, Solana JS, Soliva RS, Escrich SR, Gonz\u00e1lez MCS. N-containing heteroaryl derivatives as JAK3 kinase inhibitors. WO2011051452A1."},{"key":"10.1016\/j.bmcl.2019.126658_b0585","series-title":"The Selective pan-Janus Kinase (JAK) Inhibitor VR588 Demonstrates Potent Anti-Inflammatory Activity in a Murine Chronic House Dust Mite (HDM) Model of Asthma","first-page":"A6435","author":"Wiegman","year":"2015"},{"key":"10.1016\/j.bmcl.2019.126658_b0590","unstructured":"In Vitro Evaluation of a Novel Drug on Airway Epithelial Cells Obtained From Participants With Severe Asthma. NCT02740049. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02740049. Accessed 04\/23\/2019."},{"key":"10.1016\/j.bmcl.2019.126658_b0595","doi-asserted-by":"crossref","unstructured":"Michael C, Hongshi Y, Hyun-Hee L, et al. Estimation of Fraction Dissolved After Intratracheal Delivery of a Potent Janus Kinase Inhibitor, iJAK-001, with Low Solubility in Rat and Sheep: Impact of Preclinical PKPD on Inhaled Human Dose Projection. J Aerosol Med Pulm Drug Deliv. Ahead of print. DOI: 10.1089\/jamp.2018.1492.","DOI":"10.1089\/jamp.2018.1492"},{"key":"10.1016\/j.bmcl.2019.126658_b0600","unstructured":"Childers ML, Dinsmore C, Fuller P, et al. Cycloalkyl nitrile pyrazolo pyridones as janus kinase inhibitors. US9725445B2."},{"key":"10.1016\/j.bmcl.2019.126658_b0605","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2019.04.008","article-title":"Discovery of a class of highly potent Janus Kinase 1\/2 (JAK1\/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling","author":"Zak","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2019.126658_b0610","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1126\/science.8171324","article-title":"Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis","volume":"264","author":"Dranoff","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.bmcl.2019.126658_b0615","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa062505","article-title":"GM-CSF autoantibodies and neutrophil dysfunction in pulmonary alveolar proteinosis","volume":"356","author":"Uchida","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmcl.2019.126658_b0620","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nature13807","article-title":"Pulmonary macrophage transplantation therapy","volume":"514","author":"Suzuki","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2019.126658_b0625","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.taap.2014.06.002","article-title":"Nonclinical safety of mavrilimumab, an anti-GMCSF receptor alpha monoclonal antibody, in cynomolgus monkeys: relevance for human safety","volume":"279","author":"Ryan","year":"2014","journal-title":"Toxicol Appl Pharmacol"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X19306080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X19306080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:30:23Z","timestamp":1760772623000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X19306080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":125,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0960894X19306080"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2019.126658","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhaled Janus Kinase (JAK) inhibitors for the treatment of asthma","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2019.126658","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"126658"}}